Daftar Pustaka

Agarwal, R. and Kaye, S. (2005) 'Prognostic factors in ovarian cancer: how close are we to a complete picture?' doi: 10.1093/annonc/mdi104.

Aluloski, I. *et al.* (2017) 'Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia', *Open Access Macedonian Journal of Medical Sciences*, 5(7), p. 904. doi: 10.3889/OAMJMS.2017.215.

American Cancer Society (2014) 'What is ovarian cancer?', pp. 1–14. Available at: https://www.cancer.org/cancer/ovarian-cancer.

Andrew E Green, M. (2021) *Ovarian Cancer: Practice Essentials, Background, Pathophysiology*, *Medscape*. Available at: https://emedicine.medscape.com/article/255771-overview (Accessed: 17 September 2022).

Ascites | Johns Hopkins Medicine (no date). Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/ascites (Accessed: 22 March 2022).

Aslam Sohaib, S. A. *et al.* (2003) *Characterization of adnexal mass lesions on MR imaging*, *American Journal of Roentgenology*. doi: 10.2214/ajr.180.5.1801297.

Biggs, W. S. and Marks, S. T. (2016) 'Diagnosis and management of adnexal masses', *American Family Physician*, 93(8), pp. 676–681. Available at: www.aafp.org/afp. (Accessed: 2 January 2022).

Buy, J. N. *et al.* (1991) 'Epithelial tumors of the ovary: CT findings and correlation with US', *Radiology*, 178(3), pp. 811–818. doi: 10.1148/radiology.178.3.1994423.

Cho, S. M. *et al.* (1999) 'CT Differentiation of Ovarian Mucinous and Serous Cystadenocarcinoma', *Journal of the Korean Radiological Society*, 41(5), p. 989. doi: 10.3348/jkrs.1999.41.5.989.

Desai, A. *et al.* (2014) 'Epithelial ovarian cancer: An overview', *World journal of translational medicine*, 3(1), p. 1. doi: 10.5528/WJTM.V3.I1.1.

Epithelial ovarian cancer | Cancer Research UK (2021). Available at: https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/types/epithelial-ovarian-cancers/epithelial (Accessed: 27 December 2021).

Ford, C. E. *et al.* (no date) 'The untapped potential of ascites in ovarian cancer research and treatment'. doi: 10.1038/s41416-020-0875-x.

Forstner, R., Hricak, H. and White, S. (1995) *Review CT and MRI of ovarian cancer*, *Abdom Imaging*.

Forstner, R., Meissnitzer, M. and Cunha, T. M. (2016) 'Update on I maging of

Ovarian Cancer', *Current Radiology Reports*, 4(6). doi: 10.1007/s40134-016-0157-9.

Foti, P. V. *et al.* (2016) 'MR imaging of ovarian masses: classification and differential diagnosis', *Insights into Imaging*, 7(1), pp. 21–41. doi: 10.1007/s13244-015-0455-4.

Hassen, K. *et al.* (2011) 'Characterization of papillary projections in benign versus borderline and malignant ovarian masses on conventional and color doppler ultrasound', *American Journal of Roentgenology*, 196(6), pp. 1444–1449. doi: 10.2214/AJR.10.5014.

Jung, S. E. *et al.* (2002) 'CT and MR imaging of ovarian tumors with emphasis on differential diagnosis', *Radiographics*, 22(6), pp. 1305–1325. doi: 10.1148/rg.226025033.

Katayama, M. *et al.* (2002) 'Diffusion-weighted echo planar imaging of ovarian tumors: Is it useful to measure apparent diffusion coefficients?', *Journal of Computer Assisted Tomography*, 26(2), pp. 250–256. doi: 10.1097/00004728-200203000-00015.

Kipps, E., Tan, D. S. P. and Kaye, S. B. (2013) 'Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research', *Nature Reviews Cancer 2013 13:4*, 13(4), pp. 273–282. doi: 10.1038/nrc3432.

Lheureux, S. *et al.* (2019) 'Epithelial ovarian cancer', *The Lancet*, 393(10177), pp. 1240–1253. doi: 10.1016/S0140-6736(18)32552-2.

Li, Y. A. *et al.* (2018) 'MRI features and score for differentiating borderline from malignant epithelial ovarian tumors', *European Journal of Radiology*, 98(2013), pp. 136–142. doi: 10.1016/j.ejrad.2017.11.014.

Matulonis, U. A. *et al.* (2016) 'Ovarian cancer', *Nature Reviews Disease Primers*, 2, pp. 1–22. doi: 10.1038/nrdp.2016.61.

McDowell, S. (2017) 'Ovarian Cancer Early Detection , Diagnosis , and Staging', *American Cancer Society*, pp. 1–25. Available at: https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging.html (Accessed: 2 January 2022).

Millington, K. *et al.* (2020) 'A serous borderline ovarian tumour in a transgender male adolescent', *British Journal of Cancer 2020 124:3*, 124(3), pp. 567–569. doi: 10.1038/s41416-020-01129-4.

Momenimovahed, Z. *et al.* (2019) 'Ovarian cancer in the world: Epidemiology and risk factors', *International Journal of Women's Health*, 11, pp. 287–299. doi: 10.2147/IJWH.S197604.

Moore et al (2018) *Moore Clinically Oriented Anatomy EIGHTH EDITION*, *Wolters Kluwer*. Wolters Kluwer Health. doi: 10.1001/jama.282.15.1485.

Murphy, A. and Gaillard, F. (2015) 'MRI sequences (overview)', *Radiopaedia.org*. doi: 10.53347/RID-37346.

Outwater, E. K. *et al.* (1997) 'Ovarian fibromas and cystadenofibrornas: MRI features of the fibrous component', *Journal of Magnetic Resonance Imaging*, 7(3), pp. 465–471. doi: 10.1002/jmri.1880070303.

Pannu, H. K. *et al.* (2013) 'Clinical Study Enhancement of Ovarian Malignancy on Clinical Contrast Enhanced MRI Studies', *Obstetrics and Gynecology*, 2013. doi: 10.1155/2013/979345.

Penninkilampi, R. and Eslick, G. D. (2018) 'Perineal Talc Use and Ovarian Cancer: A Systematic Review and Meta-Analysis', *Epidemiology*, 29(1), pp. 41–49. doi: 10.1097/EDE.0000000000000745.

Reid, B. M., Permuth, J. B. and Sellers, T. A. (2017) 'Epidemiology of ovarian cancer: a review', *Cancer Biology and Medicine*, 14(1), pp. 9–32. doi: 10.20892/j.issn.2095-3941.2016.0084.

Rickard, B. P. *et al.* (2021) 'Malignant ascites in ovarian cancer: Cellular, acellular, and biophysical determinants of molecular characteristics and therapy response', *Cancers*, 13(17). doi: 10.3390/cancers13174318.

Shahrzad Ehdaivand, M. D. (2020) *Pathology Outlines - WHO classification*, *Accessed September 8th, 2020*. Available at: https://www.pathologyoutlines.com/topic/breastmalignantwhoclassificatio n.html%0Ahttps://www.pathologyoutlines.com/topic/ovarytumorwhoclass if.html (Accessed: 10 January 2022).

Smebye, M. L. *et al.* (2017) 'Bilateral ovarian carcinomas differ in the expression of metastasis-related genes', *Oncology Letters*, 13(1), pp. 184–190. doi: 10.3892/ol.2016.5384.

Sohaib, S. A. A. and Reznek, R. H. (2007) 'MR imaging in ovarian cancer', *Cancer Imaging*, 7(SPEC. ISS. A), p. S119. doi: 10.1102/1470-7330.2007.9046.

Som, P. M. *et al.* (1989) 'Chronically obstructed sinonasal secretions: observations on T1 and T2 shortening.', *https://doi.org/10.1148/radiology.172.2.2748834*, 172(2), pp. 515–520. doi: 10.1148/RADIOLOGY.172.2.2748834.

Stratton, J. F. *et al.* (2000) 'An analysis of ovarian tumor diameter and survival', *International Journal of Gynecological Cancer*, 10(6), pp. 449–451. doi: 10.1046/j.1525-1438.2000.00070.x.

Tanaka, Y. O. *et al.* (2016) 'Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis', *Cancer Imaging*, 16(1), pp. 1–9. doi: 10.1186/s40644-016-0061-9.

Thomassin-Naggara, I. *et al.* (2008) 'Epithelial ovarian tumors: Value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis', *Radiology*, 248(1), pp. 148–159. doi: 10.1148/radiol.2481071120.

Togashi, K. *et al.* (1991) 'Endometrial cysts: Diagnosis with MR imaging', *Radiology*, 180(1), pp. 73–78. doi: 10.1148/radiology.180.1.2052726.

Togashi, K. (2003) 'Ovarian cancer: The clinical role of US, CT, and MRI', *European Radiology*, 13(SUPPL. 4), pp. 87–104. doi: 10.1007/s00330-003-1964-y.

Valentin, L. *et al.* (2013) 'Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can classify them reliably as benign or malignant before surgery?', *Ultrasound in Obstetrics & Gynecology*, 41(5), pp. 570–581. doi: 10.1002/UOG.12294.

www.researchgate.net (no date) *What are the differences between enhancing and nonenhancing lesions in MRI?* Available at: https://www.researchgate.net/post/What-are-the-differences-between-enhancing-and-nonenhancing-lesions-in-MRI (Accessed: 2 January 2022).